MedPoint News

Immune checkpoint inhibitors are revolutionizing the treatment of cancer, but new research challenges the central dogma of how these drugs work.

Incumbents from the Faculty are poised to answer the call from the distinguished collegium.

Recent FoM paper in high-profile journal offers insight into how disruptions in their communication may trigger disease.

Metabolomics applies sophisticated technologies to assess the body’s metabolites, reflecting its activities and aiding in the understanding of healthy and diseased states.

Well done to all of our members on their recent success!

uOttawa’s Dr. Doug Manuel and a team of Canadian researchers have built and validated an online calculator that empowers individuals to predict their risk of cardiovascular disease. Their process was published July 23 in the CMAJ.

There is currently no cure for Amyotrophic Lateral Sclerosis (ALS), but new research published in Nature Communications coming out of the Gibbings lab is bringing us closer.

Damien D’Amours and team explore how disruptions during cell duplication can alter DNA, potentially leading to cancer, immunodeficiency, aging and other effects.

uOttawa Professor Doug Manuel is the lead author on a new report that suggests tobacco smoking rates will drop to below 10% in about 20 years.

This year’s cohort will apply biological sciences to advance heart, lung and placental function, prosthetic joint health and physician communication.

uOttawa and the Institut du savoir Montfort (ISM) launch a new position of Research Chair in partnership with the Faculties of Medicine and Education.

The purpose of this publication is to spotlight recent success stories from various academic programs, and to profile the great strides we are making in basic and clinical research.

ELT connects with faculty, staff and learners on FoM priorities.

New study shows potential for therapeutics based on immune signaling pathways, say uOttawa authors.

Study respondents say willpower biggest barrier to positive health change.